Ralliant Corporation $RAL Shares Purchased by Phocas Financial Corp.

Phocas Financial Corp. lifted its holdings in Ralliant Corporation (NYSE:RAL) by 81.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 157,116 shares of the company’s stock after purchasing an additional 70,403 shares during the period. Ralliant comprises about 1.1% of Phocas Financial Corp.’s portfolio, making the stock its 28th largest holding. Phocas Financial Corp.’s holdings in Ralliant were worth $7,999,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Westfuller Advisors LLC acquired a new stake in Ralliant in the third quarter valued at approximately $26,000. Palisade Asset Management LLC acquired a new position in shares of Ralliant during the 3rd quarter worth approximately $26,000. UMB Bank n.a. acquired a new position in shares of Ralliant during the 3rd quarter worth approximately $29,000. BOKF NA purchased a new position in shares of Ralliant during the 3rd quarter valued at approximately $29,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Ralliant during the 3rd quarter valued at approximately $30,000.

Insider Activity

In related news, SVP Amir A. Kazmi bought 2,545 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was purchased at an average price of $39.27 per share, for a total transaction of $99,942.15. Following the acquisition, the senior vice president owned 39,699 shares of the company’s stock, valued at approximately $1,558,979.73. This trade represents a 6.85% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kevin E. Bryant bought 1,250 shares of the business’s stock in a transaction on Friday, February 6th. The stock was purchased at an average cost of $39.97 per share, for a total transaction of $49,962.50. Following the transaction, the director owned 4,653 shares of the company’s stock, valued at $185,980.41. This trade represents a 36.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 8,145 shares of company stock worth $332,233 in the last three months.

Ralliant Stock Down 0.2%

Shares of RAL opened at $41.92 on Monday. The company’s 50-day moving average price is $44.96 and its 200 day moving average price is $46.72. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $57.02. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. The firm has a market cap of $4.68 billion and a P/E ratio of 21.39.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The company’s revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 23rd. Investors of record on Monday, March 9th were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Ralliant’s dividend payout ratio (DPR) is presently 10.20%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Friday, February 6th. Weiss Ratings downgraded shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a report on Thursday, February 5th. Citigroup dropped their target price on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Barclays cut their target price on shares of Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Finally, Truist Financial decreased their price target on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $50.50.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.